Cellular stress response, redox status, and vitagenes in glaucoma: A systemic oxidant disorder linked to Alzheimer's disease

Frontiers in Pharmacology

Volumn 5 JUN, Issue , 2014, Pages

  Salinaro, Angela Trovato ^a   Cornelius, Carolin ^a   Koverech, Guido ^a   Koverech, Angela ^a   Scuto, Maria ^a   Lodato, Francesca ^a   Fronte, Vincenzo ^a   Muccilli, Vera ^a   Reibaldi, Michele ^a   Longo, Antonio ^a   Uva, Maurizio G ^a   Calabrese, Vittorio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antioxidants; Free radicals; Hormesis; Stress response; Vitagenes

Indexed keywords

HEAT SHOCK PROTEIN 72; HEME OXYGENASE 1; ISOPROSTANE DERIVATIVE; OXIDOREDUCTASE; PROTEIN TRX; SIRTUIN 1; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; CELLULAR STRESS RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; F2 ISOPROSTANE GENE; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GLAUCOMA; HEME OXYGENASE 1 GENE; HOMEOSTASIS; HSP 72 GENE; HUMAN; MALE; OXIDATION REDUCTION STATE; PATHOGENESIS; PROTEIN EXPRESSION; UPREGULATION;

EID: 84904757488     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00129     Document Type: Article

References (48)

1. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and Jones, E. (2011). Alzheimer's disease. Lancet 19, 1019-1031. doi: 10.1016/S0140-6736(10)61349-9
2. Bonda, D. J., Lee, H. G., Camins, A., Pallàs, M., Casadesus, G., Smith, M. A., et al. (2011). The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic consideration. Lancet Neurol. 10, 275-279. doi: 10.1016/S1474-4422(11)70013-8
3. Bullock, R., and Hammond, G. (2003). Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17, S80-S85. doi: 10.1097/00002093-200307003-00004
4. Butterfield, D. A., Bader Lange, M. L., and Sultana, R. (2010). Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 1801, 924-929. doi: 10.1016/j.bbalip.2010.02.005
5. Butterfield, D. A., Reed, T., and Sultana, R. (2011). Roles of 3-nitrotyrosine- and 4-hydroxynonenalmodified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic. Res. 45, 59-72. doi: 10.3109/10715762.2010.520014
6. Calabrese, E. J., Iavicoli, I., and Calabrese, V. (2013). Hormesis: its impact on medicine and health. Hum. Exp. Toxicol. 32, 120-152. doi: 10.1177/0960327112455069
7. Calabrese, V., Cornelius, C., Dinkova-Kostova, A. T., Calabrese, E. J., and Mattson, M. P. (2010a). Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 13, 1763-1811. doi: 10.1089/ars.2009.3074
8. Calabrese, V., Cornelius, C., Giuffrida, A. M., and Calabrese, E. J. (2010b). Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochem. Res. 35, 1880-1915. doi: 10.1007/s11064-010-0307-z
9. Calabrese, V., Cornelius, C., Trovato, A., Cavallaro, M., Mancuso, C., Di Rienzo, L., et al. (2010c). The hormetic role of dietary antioxidants in free radical-related diseases. Curr. Pharm. Des. 16, 877-883. doi: 10.2174/138161210790883615
10. Calabrese, V., Cornelius, C., Leso, V., Trovato-Salinaro, A., Ventimiglia, B., Cavallaio, M., et al. (2012). Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim. Biophys. Acta 1822, 729-736. doi: 10.1016/j.bbadis.2011.12.003
11. Calandrella, N., Scarsella, G., Pescosolido, N., and Risuleo, G. (2007). Degenerative and apoptotic events at retinal and optic nerve level after experimental induction of ocular hypertension. Mol. Cell. Biochem. 301, 155-163. doi: 10.1007/s11010-006-9407-0
12. Cornelius, C., Trovato Salinaro, A., Scuto, M., Fronte, V., Cambria, M. T., Pennisi, M., et al. (2013). Cellular stress response, sirtuins and UCP proteins in Alzheimer disease: role of vitagenes. Immun. Ageing 10:41. doi: 10.1186/1742-4933-10-41
13. Dali-Youcef, N., Lagouge, M., Froelich, S., Koehl, C., Schoonjans, K., and Auwerx, J. (2007). Sirtuins: the "magnificent seven," function, metabolism and longevity. Ann. Med. 39, 335-345. doi: 10.1080/07853890701408194
14. De la Monte, S. M., and Wands, J. R. (2006). Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 9, 167-181.
15. Di Paola, R., Impellizzeri, D., Trovato Salinaro, A., Mazzon, E., Bellia, F., Cavallaro, M., et al. (2011). Administration of carnosine in the treatment of acute spinal cord injury. Biochem. Pharmacol. 82, 1478-1489. doi: 10.1016/j.bcp.2011.07.074
16. Drake, J., Link, C. D., and Butterfield, D. A. (2003). Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging 24, 415-420. doi: 10.1016/S0197-4580(02)00225-7
17. Dumont, M., Wille, E., Stack, C., Calingasan, N. Y., Beal, M. F., and Lin, M. T. (2009). Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 23, 2459-2466. doi: 10.1096/fj.09-132928
18. Ferreira, S. M., Lerner, S. F., Brunzini, R., Evelson, P. A., and Llesuy, S. F. (2004). Oxidative stress markers in aqueous humor of glaucoma patients. Am. J. Ophthalmol. 137, 62-69. doi: 10.1016/S0002-9394(03)00788-8
19. Guo, L., Salt, T. E., Maass, A., Luong, V., Moss, S. E., Fitzke, F. W., et al. (2006). Assessment of neuroprotective effects of glutamate modulation on glaucomarelated retinal ganglion cell apoptosis in vivo. Invest. Ophthalmol. Vis. Sci. 47, 626-633. doi: 10.1167/iovs.05-0754
20. Gupta, N., Ang, L. C., Noel de Tilly, L., Bidaisee, L., and Yucel, Y. H. (2006). Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br. J. Ophthalmol. 90, 674-678. doi: 10.1136/bjo.2005.086769
21. Gupta, N., Fong, J., Ang, L. C., and Yucel, Y. H. (2008). Retinal tau pathology in human glaucomas. Can. J. Ophthalmol. 43, 53-60. doi: 10.3129/i07-185
22. Halliwell, B. (2006). Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634-1658. doi: 10.1111/j.1471-4159.2006.03907.x
23. Herranz, D., and Serrano, M. (2010). SIRT1: recent lessons from mouse models. Nat. Rev. Cancer 10, 819-823. doi: 10.1038/nrc2962
24. Hinton, D. R., Sadun, A. A., Blanks, J. C., and Miller, C. A. (1986). Optic-nerve degeneration in Alzheimer's disease. N. Engl. J. Med. 315, 485-487. doi: 10.1056/NEJM198608213150804
25. Hirota, K., Nakamura, H., Masutani, H., and Yodoi, J. (2002). Thioredoxin superfamily and thioredoxin-inducing agents. Ann. N. Y. Acad. Sci. 957, 189-199. doi: 10.1111/j.1749-6632.2002.tb02916.x
26. Izzotti, A., Bagnis, A., and Saccà, S. C. (2006). The role of oxidative stress in glaucoma. Mutat. Res. 612, 105-114. doi: 10.1016/j.mrrev.2005.11.001
27. Kessing, L. V., Lopez, A. G., Andersen, P. K., and Kessing, S. V. (2007). No increased risk of developing Alzheimer disease in patients with glaucoma. J. Glaucoma 16, 47-51. doi: 10.1097/IJG.0b013e31802b3527
28. Mayeux, R., and Stern, Y. (2012). Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, 2-8. doi: 10.1101/cshperspect.a006239
29. McKinnon, S. J. (2003). Glaucoma: ocular Alzheimer's disease? Front. Biosci. 8:1140-1156. doi: 10.2741/1172
30. Pennisi, G., Cornelius, C., Cavallaro, M. M., Trovato Salinaro, A., Cambria, M. T., Pennisi, M., et al. (2011). Redox regulation of cellular stress response in multiple sclerosis. Biochem. Pharmacol. 82, 1490-1499. doi: 10.1016/j.bcp.2011.07.092
31. Quigley, H. A., and Broman, A. T. (2006). The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthal. 90, 262-267. doi: 10.1136/bjo.2005.081224
32. Ritov, V. B., Kelley, D. E., and Kagan, V. E. (2002). Derivatization of F2-isoprostanes with 1-pyrenyldiazomethane and their subsequent determination by fluorescence high-performance liquid chromatography. Anal. Biochem. 311, 10-18. doi: 10.1016/S0003-2697(02)00392-5
33. Rocchi, A., Pellegrini, S., Siciliano, G., and Murri, L. (2003). Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res. Bull. 61, 1-24. doi: 10.1016/S0361-9230(03)00067-4
34. Salminen, A., Kauppinen, A., Suuronen, T., and Kaarniranta, K. (2008). SIRT1 longevity factor suppresses NF-kappaB-driven immune responses: regulation of aging via NF- kappaB acetylation? Bioessays 30, 939-942. doi: 10.1002/bies.20799
35. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
36. Shieds, M. B., Ritch, R., and Krupin, T. (1996). "Classification of the glaucoma," in The Glaucomas, 2nd Edn, eds R. Ritch, M. B. Shields, and T. Krupin (St. Louis: Mosby), 717-725.
37. Siciliano, R., Barone, E., Calabrese, V., Rispoli, V., Butterfield, D. A., and Mancuso, C. (2011). Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge. CNS Neurol. Disord. Drug Targets 10, 766-776. doi: 10.2174/187152711798072356
38. Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., et al. (2002). The public health impact of Alzheimer's disease 2000-2050: potential implication of treatment advances. Annu. Rev. Public Health 23, 213-231. doi: 10.1146/annurev.publhealth.23.100901.140525
39. Smith, P., Krohn, R., Hermanson, G., Mallia, A., Gartner, F., Provenzano, M., et al. (1985). Measurement of proteins using bicinchoninic acid. Anal. Biochem. 150, 76-85. doi: 10.1016/0003-2697(85)90442-7
40. Soti, C., Nagy, E., Giricz, Z., Vigh, L., Csermely, P., and Ferdinandy, P. (2005). Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. 146, 769-780. doi: 10.1038/sj.bjp.0706396
41. Tamura, H., Kawakami, H., Kanamoto, T., Kato, T., Yokoyama, T., Sasaki, K., et al. (2006). High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J. Neurol. Sci. 246, 79-83. doi: 10.1016/j.jns.2006.02.009
42. Tanaka, T., Nakamura, H., Nishiyama, A., Hosoi, F., Masutani, H., Wada, H., et al. (2000). Redox regulation by thioredoxin superfamily: protection against oxidative stress and aging. Free Radic. Res. 33, 851-855. doi: 10.1080/10715760000301361
43. Tatton, W. G., Chalmers-Redman, R. M., and Tatton, N. A. (2001). Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur. J. Ophthalmol. 11, S12-S22.
44. Tezel, G. (2006). Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res. 25, 490-513. doi: 10.1016/j.preteyeres.2006.07.003
45. Tonissen, K. F., and Trapani, G. D. (2009). Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res. 53, 87-103. doi: 10.1002/mnfr.200700492
46. Wostyn, P., Audenaert, K., and De Deyn, P. P. (2009). Alzheimer's disease and glaucoma: is there a causal relationship? Br. J. Ophthalmol. 93, 1557-1559. doi: 10.1136/bjo.2008.148064
47. Yi, J., and Luo, J. (2010). SIRT1 and p53, effect on cancer, senescence and beyond. Biochim. Biophys. Acta 1804, 1684-1689. doi: 10.1016/j.bbapap.2010.05.002
48. Yoneda, S., Hara, H., Hirata, A., Fukushima, M., Inomata, Y., and Tanihara, H. (2005). Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn. J. Ophthalmol. 49, 106-108. doi: 10.1007/s10384-004-0156-x